tipifarnib has been researched along with farnesyl pyrophosphate in 3 studies
Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (farnesyl pyrophosphate) | Trials (farnesyl pyrophosphate) | Recent Studies (post-2010) (farnesyl pyrophosphate) |
---|---|---|---|---|---|
309 | 92 | 94 | 696 | 1 | 245 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Distefano, MD; Ochocki, JD | 1 |
Sánchez De Cos Escuín, J | 1 |
Beese, LS; Hast, MA; Hellinga, HW; Lubock, NB; Mabanglo, MF | 1 |
1 review(s) available for tipifarnib and farnesyl pyrophosphate
Article | Year |
---|---|
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
2 other study(ies) available for tipifarnib and farnesyl pyrophosphate
Article | Year |
---|---|
Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
Topics: | 2013 |
Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.
Topics: Antifungal Agents; Aspergillus fumigatus; Benzenesulfonamides; Catalytic Domain; Crystallography, X-Ray; Drug Design; Farnesyltranstransferase; Fungal Proteins; Humans; Peptides; Polyisoprenyl Phosphates; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Quinolones; Sesquiterpenes; Sulfonamides | 2014 |